CIBC World Market’s Grace Therapeutics GRCE Stock Holding History

CIBC World Market’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-334	Closed	-$6K	–	1165
2020 Q1	$6K	Buy	334 +1	+0.3%	+$35	﹤0.01%	972
2019 Q4	$39K	Buy	+333	New	+$32.9K	﹤0.01%	1105

Other funds holding GRCE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JLBC

J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

CIBC World Market's GRCE Position: Q2 2020 in Review

CIBC World Market sold out of Grace Therapeutics (GRCE) in Q2 2020, closing a stake of 334 shares — an estimated $6K sold.

CIBC World Market first reported a position in GRCE in Q4 2019 and held it in 2 quarters. The position peaked at $39K in Q4 2019. 25 funds tracked by Wall St. Rank hold GRCE as of Q2 2020.

CIBC World Market reported no remaining Grace Therapeutics position as of Q2 2020 after selling out during the quarter.
CIBC World Market sold 334 Grace Therapeutics shares in Q2 2020, an estimated $6K.
CIBC World Market first reported a position in Grace Therapeutics in Q4 2019 and held it in 2 quarters.
CIBC World Market's Grace Therapeutics position peaked at $39K in Q4 2019.
25 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2020.

Based on CIBC World Market's 13F filing for Q2 2020, filed 13 Aug 2020.